Establishment Labs Reports First Quarter 2026 Financial Results
Establishment Labs, a global medical technology firm focused on women’s health, reported a revenue of $59.9 million for Q1 2026, reflecting a 44.7% increase compared to the same period in 2025. The company has raised its revenue guidance for the year to between $266.5 million and $268.5 million, with $19.6 million in Motiva sales recorded in the United States.
NEW YORK–(BUSINESS WIRE)—- $ESTA #Breast–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2026. First Quarter Highlights and Outlook (Unaudited) Revenue of $59.9 million, up 44.7% from Q1 2025, with guidance raised to $266.5 million to $268.5 million $19.6 million of Motiva sales in the United State